Carregant...
PD-L1 blockade enhances anti-tumor efficacy of NK cells
Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors. Hence, strategies that increase PD-L1 expression and tumor infiltration should make more patients eligible for PD-1/PD-L1 blockade...
Guardat en:
| Publicat a: | Oncoimmunology |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6205063/ https://ncbi.nlm.nih.gov/pubmed/30377572 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1509819 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|